Table 2. Heterogeneity of classification, number/size of studies and populations/ancestries of cardiovascular GWAS.
| Traits | Number of studies | Approximate size of largest studies (discovery + replication combined) | Populations |
|---|---|---|---|
| Type II diabetes | 51* | 40,000 cases, 160,000 controls (36) | Broad range—European, South Asian and East Asian ancestries |
| Lipids—Chol, HDL, LDL, lipoprotein | 49 | 190,000 individuals (24) | Predominantly European, some East Asian ancestries |
| Ischaemic heart disease—myocardial infarction, coronary artery disease (combined endpoint) | 9 | 75,000 cases, 260,000 controls [(37) CAD], 380,00 cases, 125,000 controls [(38) MI] | Predominantly European, some other ancestries in largest studies |
| Stroke—stroke, ischaemic stroke, small vessel or large artery stroke | 13 | 25,000 cases, 90,000 controls (39) | Predominantly European |
| Chronic kidney disease—chronic kidney disease, ESRF (small samples), Creatinine and kidney function decline | 8 | 90,000 individuals (40) | Predominantly European |
| Heart failure | 2 | 22,000 individuals (41) | Predominantly European |
Summary characteristics of GWAS studies as derived from GWAS catalog (https://www.ebi.ac.uk/gwas/). *, not including GWAS studies on “glycosylated haemoglobin A1c”. LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol.